Huai Qi Huang-induced Apoptosis via Down-regulating PRKCH and Inhibiting RAF/MEK/ERK Pathway in Ph⁺ Leukemia Cells

Abstract

Imatinib mesylate (IM) is the first-line treatment for Philadelphia (Ph) chromosomal positive leukemia by inhibiting phosphorylation of substrates via binding to the ABL kinase domain. Because of the drug resistance, side effects and the high cost of IM, it is necessary to find anti-cancer drugs with relatively low toxicity and cost, and enhanced efficacy, such as traditional Chinese medicines (TCMs). As one of TCMs, Huai Qi Huang (HQH) was chosen to treat BV173 and K562 cells. Various concentrations of HQH were added to cells for 24–72 h. Co-treatment of HQH and trametinib, an MEK inhibitor, was used to verify the synergistic effects on cell viability and apoptosis. Knockdown and overexpression of mitogen-activated protein kinase kinase 4 (MEK4) were implemented to demonstrate the role of MEK in cell apoptosis. Cell viability and apoptosis were measured by cell counting kit-8 assay (CCK8) and flow cytometry, respectively. Western blotting and real-time quantitative PCR (RT-qPCR) were used to assess protein and mRNA expression levels, respectively. The results showed that HQH inhibited survival and promoted apoptosis of BV173 and K562 cells in a dose-dependent manner, accompanied with down-regulation of PRKCH mRNA as well as CRAF, MEK4, phospho-ERK (pERK) and BCL2 proteins, and up-regulation of cleaved caspase3 protein. Co-treatment of HQH and trametinib had a synergistic effect on inhibiting survival and promoting apoptosis. MEK4 knockdown increased apoptosis, and had a synergistic effect with HQH. In contrast, MEK4 overexpression decreased apoptosis, and had the opposite effect with HQH. Collectively, the results of this study may identify a therapeutic mechanism of HQH on promoting apoptosis, and provide a potential option for treatment of Ph⁺ leukemia.

Keywords

Huai Qi Huang / leukemia / apoptosis / BCR-ABL / RAF/MEK/ERK

References

[1] DeiningerMW, VieiraS, MendiolaR, et al.. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res, 2000, 60(7): 2049-2055

[2] AnX, TiwariAK, SunY, et al.. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res, 2010, 34(10): 1255-1268

[3] von BubnoffN, PeschelC, DuysterJ. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia, 2003, 17(5): 829

[4] La RoseeP, DeiningerMW. Resistance to imatinib: mutations and beyond. Semin Hematol, 2010, 47(4): 335

[5] LeeHJ, ThompsonJE, WangES, et al.. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer, 2011, 117(8): 1583-1594

[6] PhillipsKM, Pinilla-IbarzJ, SotomayorE, et al.. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer, 2013, 21(4): 1097-1103

[7] Experts in Chronic Myeloid Leukemia.. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013, 121(22): 4439-4442

[8] ThatteU, BagadeyS, DahanukarS. Modulation of programmed cell death by medicinal plants. Cell Mol Biol (Noisy-le-grand), 2000, 46(1): 199-214

[9] VickersA. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest, 2002, 20(7–8): 1069-1079

[10] ZhangN, KongX, YanS, et al.. Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci, 2010, 101(11): 2375-2383

[11] SongX, LiY, ZhangH, et al.. The anticancer effect of Huaier (Review). Oncol Rep, 2015, 34(1): 12-21

[12] ChenQ, ShuC, LaurenceAD, et al.. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut, 2018, 67(11): 2006-2016

[13] FangL, ZhangY, ZangY, et al.. HP-1 inhibits the progression of ccRCC and enhances sunitinib therapeutic effects by suppressing EMT. Carbohydr Polym, 2019, 223: 115109

[14] MaY, WangC, ZhangQ, et al.. The effects of polysaccharides from Auricularia auricula (Huaier) in adjuvant anti-gastrointestinal cancer therapy: A systematic review and network meta-analysis. Pharmacol Res, 2018, 132: 80-89

[15] LuoZ, HuX, XiongH, et al.. A polysaccharide from Huaier induced apoptosis in MCF-7 breast cancer cells via down-regulation of MTDH protein. Carbohydr Polym, 2016, 151: 1027-1033

[16] SunY, SunT, WangF, et al.. A polysaccharide from the fungi of Huaier exhibits anti-tumor potential and immunomodulatory effects. Carbohydr Polym, 2013, 92(1): 577-582

[17] HuB, YanW, WangM, et al.. Huaier polysaccharide inhibits the stem-like characteristics of ERalpha-36(high) triple negative breast cancer cells via inactivation of the ERalpha-36 signaling pathway. Int J Biol Sci, 2019, 15(7): 1358-1367

[18] QuP, HanJ, QiuY, et al.. Huaier extract enhances the treatment efficacy of imatinib in Ik6(+) Ph(+) acute lymphoblastic leukemia. Biomed Pharmacother, 2019, 117: 109071

[19] WangY, LvH, XuZ, et al.. Huaier n-butanol extract suppresses proliferation and metastasis of gastric cancer via c-Myc-Bmi1 axis. Sci Rep, 2019, 9(1): 447

[20] TaoY, ShanL, XuX, et al.. Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Dow-nregulation of YAP in Hepatocellular Carcinoma. J Cancer, 2018, 9(21): 3962-3970

[21] Biosci Rep, 2017, 37(6):

[22] LiT, MaoJ, HuangL, et al.. Huaiqihuang may protect from proteinuria by resisting MPC5 podocyte damage via targeting p-ERK/CHOP pathway. Bosn J Basic Med Sci, 2016, 16(3): 193-200

[23] LiLT, ShiMY, WeiSY, et al.. Huai Qi Huang ameliorates proteinuria and hematuria in mild IgA nephropathy patients: a prospective randomized controlled study. J Formos Med Assoc, 2013, 112(12): 766-772

[24] DuanSB, PanP, XuQ, et al.. Preliminary study of Huai Qi Huang granules delay the development of primary glomerular diseases in human. Ren Fail, 2014, 36(9): 1407-1410

[25] LiuH, SunW, GuLB, et al.. Huaiqihuang Granules () reduce proteinuria by enhancing nephrin expression and regulating necrosis factor kappaB signaling pathway in adriamycin-induced nephropathy. Chin J Integr Med, 2017, 23(4): 279-287

[26] PuJ, ZhangY, ZhouJ. Effect of Huai Qi Huang on Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells through miR-200a. Evid Based Complement Alternat Med, 2016, 2016: 8612190

[27] HanJ, LinM, ZhouD, et al.. Huang Qi Huai Granules Induce Apoptosis in Acute Lymphoblastic Leukemia Cells through the Akt/FoxO1 Pathway. Cell Physiol Biochem, 2016, 38(5): 1803-1814

[28] MaL, ShanY, BaiR, et al.. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med, 2014, 6(252): 121

[29] LiuH, ZangC, FennerMH, et al.. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood, 2006, 107(9): 3683-3692

[30] ColicelliJ. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal, 2010, 3(139): e6

[31] SteelmanLS, PohnertSC, SheltonJG, et al.. JAK/ STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 2004, 18(2): 189-218

[32] SavageKJ. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program, 2005267-277

[33] VilimasT, MascarenhasJ, PalomeroT, et al.. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med, 2007, 13(1): 70-77

[34] LitoP, SaborowskiA, YueJ, et al.. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell, 2014, 25(5): 697-710

[35] JingJ, GreshockJ, HolbrookJD, et al.. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther, 2012, 11(3): 720-729

[36] LeonardJT, RaessPW, DunlapJ, et al.. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent. J Hematol Oncol, 2016, 9: 31

[37] BurgessMR, HwangE, FirestoneAJ, et al.. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood, 2014, 124(26): 3947-3955

[38] YuJ, LiuH, LeiJ, et al.. Antitumor activity of chloroform fraction of Scutellaria barbata and its active constituents. Phytother Res, 2007, 21(9): 817-822

[39] HarhajiL, MijatovicS, Maksimovic-IvanicD, et al.. Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: in vitro and in vivo study. Food Chem Toxicol, 2008, 46(5): 1825

[40] RashidS, UnyayarA, MazmanciMA, et al.. A study of anti-cancer effects of Funalia trogii in vitro and in vivo. Food Chem Toxicol, 2011, 49(7): 1477-1483

[41] SongX, LiY, ZhangH, et al.. The anticancer effect of Huaier (Review). Oncol Rep, 2015, 34(1): 12-21

[42] ReddyKB, NabhaSM, AtanaskovaN. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 2003, 22(4): 395-403

[43] YanL, LiuX, YinA, et al.. Huaier aqueous extract inhibits cervical cancer cell proliferation via JNK/p38 pathway. Int J Oncol, 2015, 47(3): 1054-1060

[44] WangX, ZhangN, HuoQ, et al.. Anti-angiogenic and antitumor activities of Huaier aqueous extract. Oncol Rep, 2012, 28(4): 1167-1175

[45] AndrewsMC, TurnerN, BoydJ, et al.. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Clin Cancer Res, 2015, 21(23): 5222-5234

[46] JonesCL, GearheartCM, FosmireS, et al.. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood, 2015, 126(19): 2202-2212

[47] ZhangH, GordonR, LiW, et al.. Genistein treatment duration effects biomarkers of cell motility in human prostate. PLoS One, 2019, 14(3): e214078

[48] PaveseJM, OgdenIM, VollEA, et al.. Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS One, 2014, 9(7): e102289

[49] CunninghamSC, GallmeierE, HuclT, et al.. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res, 2006, 66(11): 5560-5564

[50] XuL, DingY, CatalonaWJ, et al.. MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst, 2009, 101(16): 1141-1155

[51] CorbinAS, AgarwalA, LoriauxM, et al.. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest, 2011, 121(1): 396-409

[52] HamiltonA, HelgasonGV, SchemionekM, et al.. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 2012, 119(6): 1501-1510